Partners News Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders
16 April 2021

Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders

Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. The partnership aims to accelerate the development of a diagnostic technology platform that improves the standard of care for patients with bleeding disorders.

Enzyre was founded in 2016 with the mission to save patients from bleeding to death with their Enzypad technology. Their vision is to create a point of care diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.

Read the Takeda announcement here: https://lnkd.in/dJSqpRk

Related news items


Meet BabyChecker!

24 September 2021

On September 20th, 2021, Delft Imaging launched BabyChecker: an affordable and portable smartphone-based ultrasound solution.

read more

New start-up Patholyt will bring AI research into pathology diagnostics

21 September 2021

Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.

read more

Radboudumc enhances Luchtbrug in collaboration with FindAir

17 August 2021

Luchtbrug is a platform for online asthma care for children and young people, which (partly) replaces outpatient visits.

read more

ScreenPoint Medical raises $28 million for further development Series C funding led by Insight Partners

2 August 2021

ScreenPoint Medical has raised $28 million in a Series C financing. ScreenPoint Medical is a spin-off of the Radboudumc.

read more

Radboudumc and SyncVR Medical looking to boost the use of virtual reality in healthcare

15 July 2021

Aiming to provide better care with the help of virtual reality applications, Radboudumc is going to collaborate intensively with startup SyncVR Medical. To this end, the two partners signed a two-year collaboration agreement.

read more

Teaming up to develop an effective cure for mycobacterium abscessus disease using inhaled tigecycline

7 July 2021

PureIMS, Radboudumc, and Sever Pharma Solutions are now teaming up to develop an effective cure for this chronic and debilitating disease.

read more